Experienced in Ewing Sarcoma

Qinghua H. Zhou

Chengdu, CN 
Experienced in Ewing Sarcoma
Chengdu, CN 
OverviewLocationsClinical Research

Overview

Qinghua Zhou practices in Chengdu, China. Zhou is rated as an Experienced expert by MediFind in the treatment of Ewing Sarcoma. Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), SVC Obstruction, Endoscopy, and Tissue Biopsy.

Their clinical research consists of co-authoring 345 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Ewing Sarcoma.

Locations

Chengdu, 610041, China
Other Locations
Tianjin, 300011, China
China
Hangzhou, 311200, China
Chinese Academy Of Medical Sciences And Peking Union Medical College, Beijing, 100021, China
Jinan, 519000, China
Zoucheng, China
Shengyang, 110042, China
154, Anshan Road, Xiaobailou, 300052, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: Tepotinib, Osimertinib
Study Phase: Phase 2
View 1 Less Clinical Trial

344 Total Publications

Study on subacute toxicity of p-chloro-m-xylenol in rats
Study on subacute toxicity of p-chloro-m-xylenol in rats
Journal: Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
Published: August 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhou's expertise for a condition
ConditionClose
    View All 31 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile